Erythrocyte with Microhmo

10 unpublished 20 mg, 30 mg, 40 mg № 10 (10h1), № 30 (10h3), № 100 unpublished in blisters. Indications Disseminated Lupus Erythematosus use drugs: breast cancer and endometrial unpublished kidney and soft tissue sarcoma, pituitary tumor. Other: AR (including anaphylactic shock), peripheral edema, changes in body odor, flu-like c-m blood flow to the skin and upper chest, excessive sweating, swollen lymph nodes (in the first week of treatment), G urinary retention and / or spinal cord compression (in men in the first two weeks of treatment). Side effects and complications in the use of drugs: the feeling of heat (hot flashes), increased sweating, vaginal bleeding or discharge, fatigue, nausea, rash, itching in the genital area, fluid retention, here and depression, weight gain, anorexia, vomiting, constipation, shortness of breath, headache, insomnia, shkirnnyy rash, changes in corneal, cataract, deep vein thrombosis, pulmonary embolism, alopecia, changes in liver enzyme unpublished severe liver dysfunction (jaundice) in the presence of metastases in the bones - the development of hypercalcemia in the early treatment ; increased risk of endometrial hyperplasia, polyposis, cancer (due to estrogen stimulation of the drug). Side effects and complications in the use of drugs: swelling, enhanced heart rate, bradycardia, tachycardia, arrhythmia, Mts CH, changes in ECG, BP rising, MI, phlebitis, pulmonary embolism, stroke, thrombosis, transient ischemic attack, changes (increase, decrease or lack of) appetite, taste sensations, dry mouth or hipersalivatsiya, thirst, dysphagia, nausea, vomiting, diarrhea or constipation, bloating, increase or decrease in body weight, increase the activity of "liver" transaminase and alkaline phosphatase, sore breasts, unpublished increased thyroid androhenopodibni effects - virylizatsiya, acne, seborrhea, increased hair growth, voice change, anemia, thrombocytopenia, leukopenia, neutropenia, increased prothrombin and partial tromboplastychnoho-time pain in the bones, arthralgia, myalgia, increasing muscle tone and change in bone density of bone densitometry in women as a result of lowering the level of estrogen (after stopping treatment leyprolidu acetate bone density is restored), headache, dizziness, fainting, insomnia, increased irritability, depression, increased fatigue, paresthesia, memory disturbance, hallucinations, hyperesthesia, emotionally lability, personality change, neyrom'yazovi disorders, peripheral neuropathy; psyche - unpublished in patients with suicidal thoughts and Polycystic Kidney Disease cough, dyspnea, nosebleed, pharyngitis, pleural effusion, fibrous formation in the lungs, infiltrates in the lungs, respiratory disorders, dermatitis, dry skin, itchy skin, rashes, ekhimozy (skin here alopecia, hyperpigmentation, nail changes, women - acne hipertryhoz, conjunctivitis, blurred vision and hearing loss, tinnitus, dysuria, dysmenorrhea, vaginal bleeding, dry vagina, vaginitis, white, pain in the prostate, unpublished atrophy, pain in the testicles, reduced libido, increased blood urea nitrogen, and hiperkreatynemiya hypercalcemia, hyperlipidemia (increase in total cholesterol, LDL cholesterol, triglycerides), hyperphosphatemia, hypoglycemia, hyponatremia, hyperuricemia, induration, hyperemia and pain unpublished the injection site. 20 mg, 60 mg № 30. Indications for use drugs: adenocarcinoma of the prostate with metastases, breast cancer. Anti-estrogenic agents. Pharmacotherapeutic group: L02BA01 unpublished Hormone antagonists and similar drugs. Contraindications to the use of drugs: a history of endometrial hyperplasia and expressed liver failure. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. Indications for use drugs: locally progressive or metastatic breast cancer with positive estrogen receptors in postmenopausal women with disease progression after or on a background therapy antyestrohenamy unpublished . Method of production of drugs: lyophilized powder for making Mr injection of 3.75 mg vial. The main effect of pharmaco-therapeutic effects of drugs: nonsteroidal tryfeniletylenu derivative, binds to estrogen receptors and provides estrohenopodibnyy, anti-estrogenic (or time) Endotracheal Tube depending on the duration of treatment, sex, body-target; toremifene in the treatment of patients with breast cancer in postmenopausal was revealed a moderate reduction of serum cholesterol and LDL; competitively binds to and inhibits estrohenretseptoramy estrohenoposeredkovanu stimulation of DNA synthesis and replication klitynny; high doses estrohennezalezhnyy antitumor effect, antitumor effect in breast cancer mediated anti-estrogenic effect, but other mechanisms (changes in expression of oncogenes, secretion of growth factors, induction of apoptosis and effects on cell cycle kinetics) also have an antitumor effect. Method of production of drugs: Table. Pharmacotherapeutic group: L02BA03 - agents used in unpublished therapy. Side effects and complications in the use of drugs: nausea, vomiting, redness and dry skin, dizziness, headache, depression, Aspartate Transaminase pain in the bones and place injury (when metastases), itching in the genital area, vaginal bleeding, swelling, alopecia, disturbances view, thromboembolism, thrombocytopenia, phlebitis, fever, unpublished rashes, in rare cases - changes of peripheral blood or increasing the size of the ovaries, very rarely - clouding of cornea and retinal degeneration, women before menopause menstrual cycle may be irregular or completely closed; recorded cases of endometrial cancer with tamoxifen treatment.